

PERSONAL INFORMATION

Massimiliano Filosto

WORK EXPERIENCE

September 2020- Present

Associate Professor of Neurology

University of Brescia (Italy)

Clinical research and teaching activity on Neuromuscular Diseases

September 2020- Present

Clinical Director

NeMO-Brescia Clinical Center for Neuromuscular Diseases (Italy)

Clinical activity on Neuromuscular Diseases

September 2004-September 2020

Coordinator

Center for Neuromuscular Diseases including ALS Center and Muscle Biopsies Center (Italy)

September 2004-September 2020

Neurologist

Department of Neurological Sciences and Vision, Unit of Neurology, ASST Spedali Civili, Brescia, Italy (Italy)

June 2000-August 2004

Neurologist

ASL 2 Savonese (Italy)

EDUCATION AND TRAINING

September 1993-

Degree M.D., with honor

University of Catania (Italy)

1995- 1999

Specialization in Neurology, with honor

University of Verona (Italy)

2000- 2003

Ph.D. in Neurosciences

University of Verona (Italy)

2002- 2003

Postdoctoral Research Fellow

Department of Neurology, Columbia University, New York, USA (United States)

ADDITIONAL INFORMATION

Expertise

Academic Role

Prof. Filosto is Associate Professor of Neurology at the Department of Clinical and Experimental Sciences, University of Brescia.

Clinical Role

Prof. Filosto is Director of NeMO-Brescia Clinical Center for Neuromuscular Diseases, Brescia, Italy.

Scientific Activity

The main interests in the field of neurosciences are muscle, nerve and motor neuron diseases. His work focuses on metabolic myopathies, ALS,SMA, muscular dystrophies, inflammatory neuropathies, genotype/phenotype relations, epigenetic and pathological findings in mitochondrial diseases and muscle glycogenoses.

He is or has been "reviewer" for Neurological Sciences (Italy), BMC Neurology (UK), Southern Medical Journal (USA), CNS Spectrum (USA), Current Alzheimer Research (USA), European Journal of Neurology (UK), Pathology Research International (USA), BMC Medical Genetics (UK), Neurotoxicity Research (USA), Mitochondrion (USA), Journal of Neurology (Germany), Neuroepidemiology (New Zealand), Clinical Neurology and Neurosurgery (Belgium), Muscle and Nerve (USA), PLoS ONE (U.K.), Movement Disorders (USA/Spain), Seizure - European Journal of Epilepsy (UK), BMJ Case Reports (UK), Digestive and Liver Disease (Italy), Brain Research (USA), BioMed Research International (Egypt, USA), Journal of Nephrology (Italy), Clinical Genetics (Canada), Journal of The Neurological Sciences (USA), Biochemical Genetics (USA), Neuromuscular Disorders (UK), Austin Journal of Musculoskeletal Disorders (USA), Molecular Genetics and Metabolism (USA), Computers in Biology and Medicine (USA), BioMed Research International (Egypt, USA), Informatics in Medicine Unlocked (USA), Neuroscience Letters (USA) Current Pharmaceutical Design (USA), Diseases of the Esophagus (USA), Endocrinology Clinical Research (USA), Ophthalmic Plastic and Reconstructive Surgery (USA), International Journal of Molecular Sciences (Switzerland), Epigenomics (USA), Scientific Reports-Nature (UK), Journal of Clinical Medicine (Switzerland), HSOA Journal of Human Endocrinology (USA), Frontiers in Neurology (Switzerland), Frontiers in Physiology (Switzerland), Molecules (Switzerland), American Journal of Alzheimer Disease & Other Dementias (United Kingdom), Human Mutation (USA), Case Reports in Medicine (Egypt, USA), Frontiers in Pharmacology (Switzerland), Annals of Neurology (USA), Orphanet Journal of Rare Diseases (Europe), Acta Myologica (Italy), World Journal of Surgical Oncology (BioMed Central, UK), Journal of Medical Case Report (Canada), Neurology Research International (UK), Annals of Clinical and Translational Neurology (USA), Drugs in Context (UK), JAMA Neurology (USA), Cells (Switzerland), Journal of Affective Disorders (USA, Italy), BMC Neurology (UK), BMC Musculoskeletal Disorders (UK), Journal of Translational Genetics and Genomics (China, USA), Molecular Genetics and Metabolism Reports (USA), eNeurologicalSci (World Federation of Neurology), Clinical Case Reports (UK), Journal of Integrative Neuroscience (Hong Kong), Current Drug Targets (USA), Journal of Medical Virology (USA), Journal of Neuroimmunology (USA), American Journal of Case Reports (USA), Case Report in Rheumatology (Egypt, USA), Acta Neurologica Belgica (Belgio), Children (Switzerland), Brain Communications (UK).

He's part of the Editorial Board of the journals Case Reports in Neurological Medicine, Frontiers in Neurology, Neurological Sciences, Acta Myologica, Current Pharmaceutical Biotechnology, Journal of Clinical Medicine, Current Drugs Targets, Frontiers in Neuroscience, Frontiers in Aging Neuroscience, Journal of Translational Genetics and Genomics, Journal of Integrative Neuroscience, Cells, International Journal of Clinical Practice.

Publications Prof. Filosto is author- coauthor of more than 200 papers on PubMed-indexed international journals, six book chapters, one book as an Editor and more than 300 abstracts for national and international congresses.

His Scopus H-index is 43; his Google Scholar H-index is 48.

Projects Principal Investigator: Genetic and environmental predictors of early onset of Amyotrophic Lateral Sclerosis, coordinator Dott. E. Beghi, Istituto di Ricerche Farmacologiche "Mario Negri", Milano
Principal Investigator: La terapia delle polineuropatie disimmuni croniche con immunoglobuline sottocute. Studio retrospettivo nazionale, coordinator Dr. D. Cocito, Torino
Principal Investigator: Studio multicentrico, randomizzato in doppio cieco sugli effetti dell'uso combinato di sali di litio e riluzolo nella sclerosi laterale amiotrofica (SLA), coordinator Dott. M. Pocchiari, Istituto Superiore di Sanita, Roma
Principal Investigator: Euromotor European Mutidisciplinary ALS network identification to cure motor neuron de generation (FP/72007-2013), coordinator Dott. A. Chio, Universita di Torino
Principal Investigator: Efficacia della terapia con enzima ricombinante, enzyme replacement therapy (ERT), mediante valutazione del quadro bioptico muscolare in pazienti affetti da Malattia di Pompe. Confronto fra alterazioni istopatologiche prima e dopo terapia, coordinator Dr. M. Moggio, Milano
Primo sub-investigatore (P.I. A. Padovani): Amyotrophic Lateral Sclerosis, sport, physical activity and trauma: an international case-control study on genetic and environmental risk factors (aderente al progetto EURALS- European ALS Registry), coordinator Dott. E. Beghi, Istituto di Ricerche Farmacologiche "Mario Negri", Milano
Primo sub-investigatore (P.I. A. Padovani): Safety and efficacy of erythropoietin in amyotrophic lateral sclerosis: a randomized, placebo-controlled clinical trial, coordinator Dott. G. Lauria, IRCCS

Fondazione Istituto Neurologico "Carlo Besta" Milano

Collaborator: Genome-wide association (GWA) in SLA sporadica, coordinator Prof. V. Silani, Milano

Collaborator: Studio della possibile associazione tra la vaccinazione influenzale stagionale e l'insorgenza della Sindrome di Guillain-Barre, coordinator Dott. R. D'Alessandro, Università degli Studi di Bologna

Collaborator: Neuropatia acuta delle piccole fibre nervose cutanee nei pazienti in condizioni critiche, CRIMYNEs (CRITICAL Illness MYopathy and NEuropathy skin), coordinator Prof. N. Latronico, Brescia

Collaborator: Neuropatia acuta delle piccole fibre nervose cutanee nei pazienti in condizioni critiche - Studio CRINE (CRITICAL Illness Neuropathy of small Epidermal nerves), coordinator Prof. N. Latronico

Collaborator: Sviluppo e validazione di un network nazionale per la creazione del registro italiano delle malattie mitocondriali, Fondazione Telethon (Telethon-UILDM 2010)

Principal Investigator: Impatto emotivo e psicosociale dello sport nelle malattie neuromuscolari, coordinator Prof. Giuseppe Vita, Università di Messina, Messina

Principal Investigator: Edarav-ALS (The Italian multicenter experience with intravenous administration of Edaravone in Amyotrophic Lateral Sclerosis patients according the National Law 648/96: an observational study), coordinator Nemo-Milano

Principal Investigator: Studio retrospettivo di valutazione di effetto e sicurezza del trattamento con Nusinersen nei pazienti affetti da atrofia muscolare spinale in età adulta (SMADU), coordinator Dr. L. Maggi, Istituto C. Besta, Milano

Principal Investigator (until 13.09.20): The effects of RNS60 on ALS biomarkers, coordinator Dr. E. Beghi, Istituto Mario Negri, Milano

Principal Investigator (until 13.09.20): SLALOM (Registro Lombardo della Sclerosi Laterale Amiotrofica), coordinator Dr. E. Beghi, Istituto Mario Negri, Milano

Principal Investigator (until 13.09.20): Un database italiano per la valutazione della diagnosi, patogenesi e risposta alla terapia dei pazienti affetti da Neuropatia Motoria Multifocale e sue varianti - IDAM, coordinator Prof. E. Nobile-Orazio, Milano

Primo sub-investigatore (until 13.09.20): Validazione del questionario DYMUS (DYsphagia in Multiple Sclerosis) come strumento per la valutazione della disfagia nei pazienti con SLA (DYsphagia in Amyotrophic Lateral Sclerosis - DYALS), coordinator Dr. L. Diamanti, Pavia

Coordinatore (until 13.09.20): Impact of COVID-19 infection on a Lombard population of ALS patients, coordinator Dr. M. Filosto, ASST Spedali Civili, Brescia

Coordinatore (until 13.09.20): Assessing frequency and features of SARS-COV-2-related acute immunomediated neuropathies in northern Italy, coordinator Dr. M. Filosto, ASST Spedali Civili, Brescia

Principal Investigator: Late-onset Pompe early diagnosis (LOPED), coordinator Prof. A. Toscano, Università di Messina

Principal Investigator: A randomized, double-blind, placebo-controlled, multicenter, parallel group, dose-finding, pivotal, phase IIb/III study to evaluate the efficacy, safety and tolerability of intravenous BYM338 at 52 weeks on physical function, muscle strength, and mobility and additional long-term safety up to 2 years in patients with sporadic inclusion body myositis. Protocollo: CBYM338B2203, Novartis, coordinator Dr. M. Mirabella, Università Cattolica, Roma

Coordinatore: Estensione dello studio di fase IIb/III CBYM338B2203 per valutare l'efficacia, la sicurezza e la tollerabilità a lungo termine di BYM338 somministrato per via endovenosa in pazienti con miosite sporadica da corpi inclusi. EUDRACT 2015-001411-12, Novartis

Principal Investigator: Studio clinico I10E-1302: An European, multicentre, efficacy and safety study of I10E in initial and maintenance treatments of patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). LFB

Principal Investigator: Studio COMET (COMparative Enzyme replacement Trial with neoGAA versus rhGAA), Sanofi Genzyme

Principal Investigator: Studio familiare ed analisi dell'esoma per identificare i fattori genetici associati alla variabilità clinica della Malattia di Pompe ad esordio tardivo (Late Onset Pompe Disease - LOPD), coordinatore Prof. C. Danesino, Pavia

Sub-investigatore (P.I. A. Padovani) (until 13.09.20): Pompe Registry, Sanofi Genzyme

Sub-investigatore (P.I. A. Padovani) (until 13.09.20): A prospective safety sub-registry to assess anaphylaxis and severe allergic reactions and severe cutaneous and systemic immune-mediated reactions with alglucosidasi alfa treatment, Sanofi Genzyme

Principal Investigator (until 13.09.20): A Phase 2 Placebo-Controlled, Double-Blind, Randomized

Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Idiopathic Small Fibre Neuropathy or Diabetes Mellitus with Confirmed Small Fibre Neuropathy. Biogen

Principal Investigator (until 13.09.20): ARGX-113-1802, A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Subcutaneously Administered Efgartigimod with rHuPH20 in Adult Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Argenx

Principal Investigator (until 13.09.20): Estensione in aperto della sperimentazione ARGX-113-1802 per valutare la sicurezza, la tollerabilità e l'efficacia a lungo termine di Efgartigimod PH20 SC in pazienti affetti da polineuropatia demielinizzante infiammatoria cronica (CIDP) - STUDIO ARGX-113-190. Argenx

Principal Investigator (until 13.09.20): Protocol AG10-333:A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with symptomatic Transthyretin Amyloid Polyneuropathy (ATTRIBUTE-PN Trial). Eidos Therapeutics

Principal Investigator: Development of the Italian National Registry for FSHD, finanziato dalla Fondazione Telethon (bando Telethon-UILDMD 2011)

Principal Investigator: Building a Nation-wide Italian collaborative network for muscle glycogenoses: registry and natural history, Fondazione Telethon (Telethon-UILDMD 2013)

Principal Investigator: Phenotypic and molecular characterization of FSHD families: a systematic approach towards trial readiness Fondazione Telethon (Telethon-UILDMD 2013)

Principal Investigator: Protein misfolding Amyotrophic Lateral Sclerosis and guanabenz, a phase II RCT with utility design; protocollo PROMISE, coordinator Prof. G. Lauria, Milano (Call 2013 ARISLA)

Principal Investigator (until 13.09.20): Una rete lombarda per lo studio della Poliradiculoneuropatia Cronica Infiammatoria Demielinizzante (CIDP) (RF0180) e delle sue varianti per ottimizzare il processo diagnostico e terapeutico alla luce dei costi e del miglioramento della qualità della vita, Bando di Ricerca Indipendente 2012 di Regione Lombardia, Coordinator Prof. E. Nobile Orazio

Principal Investigator (until 13.09.20): Translating molecular mechanisms into ALS risk and patient's well-being (TRANS-ALS), FRRB 2015 (Fondazione Regionale per la Ricerca Biomedica)

Principal Investigator (until 13.09.20): Developing tools for trial readiness in primary mitochondrial myopathies of the adulthood (Telethon-Mitocon, 2016)

Principal Investigator (until 13.09.20): Studio randomizzato controllato in doppio cieco con rituximab verso placebo nei pazienti con poliradiculoneuropatia cronica infiammatoria demielinizzante (CIDP) in trattamento cronico con immunoglobuline, CIDPRIT, coordinator Prof. E. Nobile-Orazio, Milano (AIFA)

Collaborator (until 13.09.20): "Rete clinica e registro di malattia per la preparazione a trial clinici nella Atrofia Muscolare Bulbo-Spinale", Telethon-UILDMD 2015

Principal Investigator: A nation-wide Italian registry for patients with muscular dystrophies and myopathies - Studio GSP18002 Telethon

Natural history of spinal muscular atrophy: long-term study and registry creation -MER-SMA-18-003 - ITASMAC SMAC Registry; Catholic University of the Sacred Heart, Prof. E. Mercuri

Principal Investigator: AB19001 "Prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase III study to compare the efficacy and safety of masitinib in combination with riluzole versus placebo in combination with riluzole in the treatment of affected patients from Amyotrophic Lateral Sclerosis (ALS) ", AB Science

Principal Investigator Biohaven - BHV2000-301 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Ambulatory and Non-Ambulatory Participants with Spinal Muscular Atrophy with Open-Label Extension (RESILIENT)

Principal Investigator A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects with Primary Mitochondrial Disease Resulting from Pathogenic Nuclear DNA Mutations (nPMD), SPIMD-301, Stealth Biotherapeutics

Memberships Since 2000 he is member of the Italian Society of Neurology and the Italian Association of Myology; since 2005 of the Italian Association of Neuropathology; since 2007 of the World Muscle Society; since 2010 of the Italian Association for the Study of the Peripheral Nervous System.

Since 2011 he is member of the Treat-NMD Neuromuscular Network (network of excellence funded by the European Commission FP6).

From 2012 to 2018 he was a member of the Board of the Italian Association of Myology (AIM).

Since 2016 he is full Individual Member of the European Academy of Neurology and participates to expert panels in neuromuscular diseases, peripheral neuropathies and motor neuron diseases. In 2021 he was elected a member of the Management Group of the EAN Scientific Panel Muscle & NMJ disorders (European Academy of Neurology) for the period 2022-2024

In 2022 he was elected a member of the Board of Directors of the Italian Association for the Study of the Peripheral Nervous System (ASNP) with a three-year term

He is a member of the Medical/Scientific Commission of the Italian Amyotrophic Lateral Sclerosis Association (AISLA), Italian Union against Muscular Dystrophies (UILDM) and Mitocon Italia.

Other Relevant Information